RHB-102 is a once daily controlled release proprietary formulation of Ondansetron. Ondansetron is marketed under various trade names including GSK’s Zofran®. RHB-102 was licensed from SCOLR Pharma, Inc. [Amex: DDD] in May 2010. As Zofran, RHB-102 is a 5-HT3 receptor antagonist and is planned to be indicated for prevention of nausea and vomiting for certain oncology patients. Two clinical PK studies were conducted and RedHill is currently executing its development plan.
Latest News
-
February 15th, 2012
RedHill Biopharma’s RHB-102 (prevention of nausea and vomiting) advanced clinical trial has began -
February 13th, 2012
RedHill Biopharma obtains FDA IND for advanced clinical trial with RHB-102 (Prevention of Nausea and Vomiting) -
February 7th, 2012
RedHill Biopharma obtains a CTA approval from Health Canada to commence an advanced trial with RHB-102 (prevention of nausea & vomiting) -
February 2nd, 2012
Mr. Gilead Raday’s interview on Israel21c, regarding RHB-102 (prevention of nausea & vomiting in cancer patients) -
January 2nd, 2012
IntelGenx, RedHill’s Development Partner in RHB-103 (Migraine) Announces Health Canada Approval for Pivotal Trial
See More News